CYTOTOXICITY OF LYMPHOCYTES FROM PATIENTS WITH CANCER OF URINARY-BLADDER - DETECTION BY A H-3-PROLINE MICROCYTOTOXICITY TEST
CYTOTOXICITY OF LYMPHOCYTES FROM PATIENTS WITH CANCER OF URINARY-BLADDER - DETECTION BY A H-3-PROLINE MICROCYTOTOXICITY TEST
复制标题
DOI：
10.1002/ijc.2910140207
复制
发表时间：
1974-01-01
影响因子：
6.4
通讯作者：
OETTGEN, HF
中科院分区：
文献类型：
--
作者：
BEAN, MA;PEES, H;OETTGEN, HF
人类淋巴细胞（用明胶沉淀、尼龙柱培养和污染红细胞的Tris NH4Cl裂解从去纤静脉血中纯化）对来自膀胱癌的T24细胞和来自其他组织的细胞培养物进行了细胞毒性（CTX）测试。CTX通过改进的微细胞毒性试验（MCT）进行评估，其中3h -脯氨酸预先标记的单层靶细胞从微孔表面丢失表明这些细胞被破坏。将与淋巴细胞孵育后仍然附着的靶细胞数量（以残差3h计数测量）与与对照淋巴细胞孵育后仍然附着的数量进行比较。结果分为三类：(1)特异性CTX（仅破坏T24细胞）；(2)非特异性CTX（破坏t24细胞和其他靶细胞）；(3)阴性（不破坏任何类型的靶细胞）。膀胱癌患者淋巴细胞中T24细胞特异性CTX的发生率（10/27）高于其他患者和正常人（2/49）（p <0.001），提示这是一种与疾病相关的现象。相比之下，非特异性CTX在膀胱患者（6/27）和其他患者（9/36）中发生的频率相同，尽管在正常人中发生的频率较低（0/13）。此外，在早期或浅表性膀胱癌患者中发现T24细胞特异性CTX的淋巴细胞较多（8/15），而在晚期膀胱癌患者中较少（2/12）。这些结果与其他人使用标准MCT测量靶细胞破坏和对靶细胞增殖影响的结果一致。
Human lymphocytes (purified from defibrinated venous blood using gelatin sedimentation, nylon column incubation, and Tris NH4Cl lysis of contaminating erythrocytes) were tested for cytotoxicity (CTX) against T24 cells derived from a carcinoma of the bladder and against cell cultures derived from other tissues. The CTX was assessed in a modified microcytotoxicity test (MCT) where loss of3H‐proline prelabelled monolayer target cells from the surface of micro‐wells indicates destruction of these cells. The number of target cells that remained attached after incubation with lymphocytes (measured as residual3H‐counts) was compared to the number that remained attached after incubation with control lymphocytes. The results were classified into three categories: (1) specific CTX (destruction only of T24 cells); (2) non‐specific CTX (destruction ofT24 cells as well as other target cells); and (3) negative (no destruction of any type of target cell). Specific CTX for T24 cells was seen more often with lymphocytes from bladder cancer patients (10/27) than from other patients and normal individuals (2/49) (p <0.001) which suggests that this is a disease‐related phenomenon. By contrast, non‐specific CTX occurred with equal frequency amopg bladder patients (6/27) and other patients (9/36), although less frequently among normal individuals (0/13). In addition, lymphocytes that showed specific CTX for T24 cells were found more often in patients with early or superficial bladder cancer (8/15) and less often in patients with advanced bladder cancer (2/12). These results are in agreement with those obtained by others who used the standard MCT that measures target‐cell destruction and influences on target‐cell proliferation.